KRAS and intrahepatic cholangiocarcinoma: In addition, the incidence of KRAS mutations was 8% in proliferative-type ICC tumors and 7% in inflammatory type ICC tumors; the incidence of BRAF mutations was 5% among proliferative-type ICC tumors and 2% among inflammatory type ICC tumors [32].